‘Euglycemic’ Ketoacidosis in a Patient With Type 2 Diabetes Being Treated With Canagliflozin.
Canagliflozin is a sodium-glucose co-transporter 2 (SGLT-2) inhibitor, one of a class of novel antiglycemic agents that are gaining in popularity in the treatment of diabetes. We describe a case in which a patient experienced difficult-to-treat metabolic ketoacidosis in the setting of canagliflozin use. A 52-year-old man with type 2 diabetes mellitus developed profound ketoacidosis without overt hyperglycemia while taking canagliflozin. Despite initiation of an insulin infusion, the metabolic acidosis persisted for 3 days. Treatment with canagliflozin was associated with development of euglycemic ketoacidosis.